The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients diagnosed with moderate to severe ulcerative colitis.
A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
The trial is an open label extension study. Eligible patients from the RPC01-3101 trial diagnosed with moderate to severe ulcerative colitis will be enrolled to receive study medication for up to 5 years or until marketed approval.
You can join if…
Open to people ages 18–75
Previous participation on a trial of RPC1063 for ulcerative colitis (UC) and may benefit from continued treatment
You CAN'T join if...
Require initiation of other therapies used in the treatment of UC
Pregnant, lactating, or have a positive serum pregnancy test
Have clinically relevant cardiovascular conditions or other relevant disease that would put the patient at risk or make interpretation of the trial difficult
University of California at San Francisco (PARENT)accepting new patients San Francisco, California, 94115, United States
High Desert Gastroenterology, Inc.accepting new patients Lancaster, California, 93534, United States
Facey Medical Foundation (Parent)accepting new patients Mission Hills, California, 91345, United States
Anaheim Clinical Trialsaccepting new patients Anaheim, California, 92801, United States
Alliance Clinical Researchaccepting new patients Oceanside, California, 92056, United States